Replies to post #83493 on Cytodyn Inc (CYDY)

[JLA Ins]

Assuming uplisting would be the only major news.. which you know is not the case.

[Scooter McCabe]

So when it uplists to either the NYSE or NASDAQ there is a lot more transparency when it comes to shorting stocks. An uplist would likely lead to a 5 dollar share price, at that point institutions and firms are able to recommend and buy the stock.

Anyone shorting into that is risking their home and kid's college fund.

[HighGrowth70]

Most likely true. NP is like the "Pied Piper" of the OTC, and investors are tiring of it.

Unusual that NP would trot Kelly out for this investor call, other than maybe he actually does have "news" to share, and that Kelly is the messenger. We'll see...

I liked to watch/listen to the Infomercials and investor calls about 2-3 years ago (after my initial investment). I tired of them during the BLA filing debacle over the last year because of the flat-out deception from NP. I regained interest in the press calls to learn from Drs Bruce and Jay when they'd share their medical insights on COVID. For newcomers to CYDY, stick around a while and you'll see the pattern with NP and tire of it.

Outside of a COVID therapy EUA gift (as Jay would say), this is going to trade with major swings. An uplist "price hike" will be short lived if it's not coupled with a COVID approval. Wider exposure means the stock will be heavily shorted with this Management team, so get ready.

Realized EPS from HIV sales is years off and the stock will respond accordingly. The pipeline of Trials is sexy; but Trial catalyst stock runs always retrace. And, they're only Phase Ib/II Trials so don't get too excited unless there is a juicy Partnership deal. Regardless, each of the Trials can fail, and years away from an NDA and EPS.